Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
A genetically reshaped human IgG1 monoclonal antibody (CAMPATH-1H) was used to treat two patients with non-Hodgkin lymphoma. Doses of 1-20 mg daily were given intravenously for up to 43 days. In both patients lymphoma cells were cleared from the blood and bone marrow and splenomegaly resolved. One p...
Asıl Yazarlar: | Hale, G, Dyer, M, Clark, MR, Phillips, J, Marcus, R, Riechmann, L, Winter, G, Waldmann, H |
---|---|
Materyal Türü: | Journal article |
Dil: | English |
Baskı/Yayın Bilgisi: |
1988
|
Benzer Materyaller
-
REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
Yazar:: Dyer, M, ve diğerleri
Baskı/Yayın Bilgisi: (1990) -
Specificity of monoclonal antibody Campath-1.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1988) -
CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
Yazar:: Hale, G, ve diğerleri
Baskı/Yayın Bilgisi: (1994) -
EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
Yazar:: Dyer, M, ve diğerleri
Baskı/Yayın Bilgisi: (1988) -
Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
Yazar:: Waldmann, H, ve diğerleri
Baskı/Yayın Bilgisi: (1985)